Medexus Pharmaceuticals is set to report its fiscal Q4 2026 results on July 2, 2026, with analysts expecting a modest EPS of CA$0.01. Investors will be keen to see if the company can maintain momentum after recent positive news on GRAFAPEX.
On July 2, 2026, Medexus Pharmaceuticals Inc (MDP.TO) will release its earnings for the fourth quarter of fiscal 2026, following a fiscal period that ended on June 30. With an EPS estimate of CA$0.01, the market will be watching closely to see if the company can turn around its recent losses and capitalize on its growth in the oncology market.
Investor takeaway: Long-term investors should watch for signs of profitability and continued product performance as Medexus navigates its growth strategies.
Advertisement
Medexus Pharmaceuticals Inc
MDP.TO
MDP.TO
Medexus Pharmaceuticals Inc
WealthAwesomeMarket cap
$142.16M
52W high
$5.10
52W low
$2.47
1W change
+25.93%
Beta
1.84
Earnings Preview: Can Medexus Turn the Corner?
With an EPS estimate of CA$0.01, Medexus Pharmaceuticals Inc is under pressure to demonstrate a recovery from its recent losses. This earnings report will be crucial for assessing the company's ability to leverage its product pipeline and improve its financial standing, especially after a year marked by significant fluctuations in its stock price.
Bull case
- Growth Potential: Medexus has shown strong performance with GRAFAPEX (treosulfan) for Injection, which could lead to better financial results.
- Market Cap Opportunity: With a market cap of CA$142.16M and a forward P/E of 16.86x, there’s room for growth if earnings meet or exceed expectations.
- Recent Developments: The recent licensing deal for UM171 Cell Therapy may create new revenue streams and strengthen the company's portfolio.
Bear case
- Negative Profit Margin: Medexus currently has a profit margin of -2.41%, highlighting ongoing challenges in achieving profitability.
- Market Sentiment: Investors may be cautious due to the company's history of losses, with a TTM EPS of CA$-0.10.
- Volatility: The stock has fluctuated between CA$2.47 and CA$5.10 over the past year, indicating potential volatility that could affect investor sentiment.
Medexus Pharmaceuticals Inc (MDP.TO)
Overview: Medexus Pharmaceuticals Inc focuses on developing and commercializing innovative pharmaceutical products, particularly in oncology. What the screen shows: The company has a market cap of CA$142.16M, with a forward P/E of 16.86x and an EPS estimate of CA$0.01 for the upcoming earnings report. Risks and watch items: Investors should be aware of the company's negative profit margin of -2.41% and the volatility in its stock price, which has ranged from CA$2.47 to CA$5.10 over the past year. For more details, visit Medexus Pharmaceuticals Inc.
Advertisement
